Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$63.13 USD
+1.20 (1.94%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $63.30 +0.17 (0.27%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Company Summary
San Diego, CA-based Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for treating metabolic and endocrine disorders.
Management is currently developing multiple candidates in early-stage to mid-stage clinical studies for biopsy-confirmed non-alcoholic steatohepatitis (NASH), obesity and X-linked adrenoleukodystrophy (X-ALD) indications.
Viking’s lead pipeline drug is VK2809, an investigational selective thyroid hormone receptor beta (TRß) agonist, which recently completed a mid-stage study in patients with biopsy-confirmed NASH. Management is in discussions with regulatory authorities to further advance this program.<...
Company Summary
San Diego, CA-based Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for treating metabolic and endocrine disorders.
Management is currently developing multiple candidates in early-stage to mid-stage clinical studies for biopsy-confirmed non-alcoholic steatohepatitis (NASH), obesity and X-linked adrenoleukodystrophy (X-ALD) indications.
Viking’s lead pipeline drug is VK2809, an investigational selective thyroid hormone receptor beta (TRß) agonist, which recently completed a mid-stage study in patients with biopsy-confirmed NASH. Management is in discussions with regulatory authorities to further advance this program.
The second candidate is VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, which is being developed across different clinical studies both as oral and subcutaneous (SC) formulations for treating obesity. Management intends to meet with the FDA to advance the SC formulation to late-stage development by early 2025.
Both VK2809 and VK2735 are part of a portfolio of five therapeutics programs that are based on small molecules licensed from Ligand Pharmaceuticals. Management is evaluating VK0214, another investigational TRß agonist, in an early-stage study for X-ALD, a rare neurogenerative disease.
Viking Therapeutics’ portfolio is currently devoid of any approved product. As a result, the company has yet to generate any revenues.
General Information
Viking Therapeutics, Inc
9920 PACIFIC HEIGHTS BLVD SUITE 350
SAN DIEGO, CA 92121
Phone: 858-704-4660
Fax: NA
Web: http://www.vikingtherapeutics.com
Email: gzante@vikingtherapeutics.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/23/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.24 |
Current Year EPS Consensus Estimate | -1.00 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 10/23/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 61.93 |
52 Week High | 99.41 |
52 Week Low | 8.28 |
Beta | 1.00 |
20 Day Moving Average | 3,065,807.75 |
Target Price Consensus | 110.82 |
4 Week | 0.85 |
12 Week | 20.16 |
YTD | 232.78 |
4 Week | -1.04 |
12 Week | 15.47 |
YTD | 176.87 |
Shares Outstanding (millions) | 110.80 |
Market Capitalization (millions) | 6,861.61 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -5.26% |
vs. Previous Quarter | 23.08% |
vs. Previous Year | NA% |
vs. Previous Quarter | NA% |
Price/Book | 7.45 |
Price/Cash Flow | NA |
Price / Sales | NA |
6/30/24 | -15.05 |
3/31/24 | -18.41 |
12/31/23 | -27.78 |
6/30/24 | -14.52 |
3/31/24 | -17.69 |
12/31/23 | -26.37 |
6/30/24 | 37.69 |
3/31/24 | 29.49 |
12/31/23 | 19.19 |
6/30/24 | 37.69 |
3/31/24 | 29.48 |
12/31/23 | 19.19 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 8.31 |
3/31/24 | 8.47 |
12/31/23 | 3.48 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |